Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1994 1
1996 1
1998 2
1999 2
2000 3
2001 5
2002 1
2003 4
2004 1
2005 4
2006 2
2008 3
2009 4
2010 3
2011 2
2012 7
2013 9
2014 8
2015 5
2016 7
2017 3
2019 3
2020 2
2021 4
Text availability
Article attribute
Article type
Publication date

Search Results

77 results
Results by year
Filters applied: . Clear all
Page 1
FAK activity in cancer-associated fibroblasts is a prognostic marker and a druggable key metastatic player in pancreatic cancer.
Zaghdoudi S, Decaup E, Belhabib I, Samain R, Cassant-Sourdy S, Rochotte J, Brunel A, Schlaepfer D, Cros J, Neuzillet C, Strehaiano M, Alard A, Tomasini R, Rajeeve V, Perraud A, Mathonnet M, Pearce OM, Martineau Y, Pyronnet S, Bousquet C, Jean C. Zaghdoudi S, et al. Among authors: pyronnet s. EMBO Mol Med. 2020 Nov 6;12(11):e12010. doi: 10.15252/emmm.202012010. Epub 2020 Oct 7. EMBO Mol Med. 2020. PMID: 33025708 Free PMC article.
eIF4A inhibition circumvents uncontrolled DNA replication mediated by 4E-BP1 loss in pancreatic cancer.
Müller D, Shin S, Goullet de Rugy T, Samain R, Baer R, Strehaiano M, Masvidal-Sanz L, Guillermet-Guibert J, Jean C, Tsukumo Y, Sonenberg N, Marion F, Guilbaud N, Hoffmann JS, Larsson O, Bousquet C, Pyronnet S, Martineau Y. Müller D, et al. Among authors: pyronnet s. JCI Insight. 2019 Nov 1;4(21):e121951. doi: 10.1172/jci.insight.121951. JCI Insight. 2019. PMID: 31672935 Free PMC article.
Antitumor effects of somatostatin.
Pyronnet S, Bousquet C, Najib S, Azar R, Laklai H, Susini C. Pyronnet S, et al. Mol Cell Endocrinol. 2008 May 14;286(1-2):230-7. doi: 10.1016/j.mce.2008.02.002. Epub 2008 Feb 13. Mol Cell Endocrinol. 2008. PMID: 18359151 Review.
Cell-cycle-dependent translational control.
Pyronnet S, Sonenberg N. Pyronnet S, et al. Curr Opin Genet Dev. 2001 Feb;11(1):13-8. doi: 10.1016/s0959-437x(00)00150-7. Curr Opin Genet Dev. 2001. PMID: 11163145 Review.
Anti-oncogenic potential of the eIF4E-binding proteins.
Martineau Y, Azar R, Bousquet C, Pyronnet S. Martineau Y, et al. Among authors: pyronnet s. Oncogene. 2013 Feb 7;32(6):671-7. doi: 10.1038/onc.2012.116. Epub 2012 Apr 16. Oncogene. 2013. PMID: 22508483 Review.
Physiology of somatostatin receptors.
Guillermet-Guibert J, Lahlou H, Cordelier P, Bousquet C, Pyronnet S, Susini C. Guillermet-Guibert J, et al. Among authors: pyronnet s. J Endocrinol Invest. 2005;28(11 Suppl International):5-9. J Endocrinol Invest. 2005. PMID: 16625838 Review.
Somatostatin analogs: does pharmacology impact antitumor efficacy?
Chalabi M, Duluc C, Caron P, Vezzosi D, Guillermet-Guibert J, Pyronnet S, Bousquet C. Chalabi M, et al. Among authors: pyronnet s. Trends Endocrinol Metab. 2014 Mar;25(3):115-27. doi: 10.1016/j.tem.2013.11.003. Epub 2014 Jan 7. Trends Endocrinol Metab. 2014. PMID: 24405892 Review.
77 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page